

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/111384 A1

(51) International Patent Classification:

C12N 15/10 (2006.01) C12N 9/78 (2006.01)
C12N 15/113 (2010.01) A61K 9/51 (2006.01)
C12N 9/22 (2006.01) A61P 7/00 (2006.01)

(21) International Application Number:

PCT/US2024/056753

(22) International Filing Date:

20 November 2024 (20.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/601,145 20 November 2023 (20.11.2023) US

(71) Applicant: **BEAM THERAPEUTICS INC.** [US/US];

238 Main Street, 9th Floor, Cambridge, Massachusetts
02142 (US).

(72) Inventors: **JOHNSON, Lei**; c/o Beam Therapeutics Inc.,

238 Main Street, 9th Floor, Cambridge, Massachusetts
02142 (US). **BOHNUUD, Tanggis**; c/o Beam Therapeu-
tics Inc., 238 Main Street, 9th Floor, Cambridge, Massachu-
setts 02142 (US). **CHENG, Lo-I**; c/o Beam Therapeutics
Inc., 238 Main Street, 9th Floor, Cambridge, Massachusetts
02142 (US). **PACKER, Michael**; c/o Beam Therapeutics
Inc., 238 Main Street, 9th Floor, Cambridge, Massachusetts
02142 (US). **CAFFERTY, Brian**; c/o Beam Therapeutics
Inc., 238 Main Street, 9th Floor, Cambridge, Massachusetts
02142 (US).

(74) Agent: **HUNTER-ENSOR, Melissa**; c/o Greenberg Trau-
rig, LLP, One International Place, Boston, Massachusetts

02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

WO 2025/111384 A1

(54) Title: COMPOSITIONS AND METHODS FOR ALTERING COMPLEMENT ACTIVATION

(57) Abstract: Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and/or reduced activity of the CFB polypeptide encoded by the polynucleotide.